Durmuş M.Köro?lu A.Demirbilek S.Özgül Ü.Özcan Ersoy M.2024-08-042024-08-0420031304-0871https://hdl.handle.net/11616/91439Celecoxib and rofecoxib that have been used in our country for treatment of osteoartritis and rheumatoid artritis are two COX-2 selective inhibitor non-steroidal antiinflammatory drugs. The aim of this study is to investigate postoperative analgesic and morphine sparing effects of single dose celecoxib or rofecoxib which were given before surgery in patients undergoing total abdominal hysterectomy. After obtaining approval from Ethics Committee, we studied 60 ASA I-II females undergoing total elective abdominal hysterectomy in a randomised, placebo controlled, double blind study. Patients were divided into 200 mg celecoxib (Group I, n=20), 50 mg rofecoxib (Group II, n=20) and placebo (Group III, n=20) groups. Anaesthesia was induced with 1.5 ?g kg -1 fentanyl, 4-6 mg kg-1 thiopental and 0.1 mg kg -1 vecuronyum. Morphine consumption, VAS scores at rest, on movement and on coughing and degree of sedation were evaluated during postoperative 2nd, 4th, 8th, 12th, and 24th h. Total morphine consumption was lesser in Group II at 8th h compared to Group III and at 12th and 24th h compared to Group I and III (p<0.05). VAS scores at rest, on coughing in Group I and II were significantly decreased during the first 24 h. There are no statistically significant differences between three groups regarding adverse effects. Although both celecoxib and rofecoxib produced a significant decrease in morphine consumption and VAS scores at rest, on movement and on coughing, we concluded that rofecoxib could produce better analgesia in early postoperative period and could decrease morphine consumption after 12th h with its long term effect.trinfo:eu-repo/semantics/closedAccessAnalgesiaCelecoxibNon-opioid analgesicsPostoperativeRofecoxibArticle3173633672-s2.0-0142074190N/A